Mr. Karr has entered into a consulting agreement with the company and will remain a member of the company’s board of directors.
Mr. Karr said: “I am proud of the tremendous accomplishments Idera has made in the discovery and development of TLR-targeted therapeutics highlighted by the recent announcement of our oncology collaboration with Merck KGaA.”